Tenecteplase Reperfusion Therapy in Acute Ischemic Cerebrovascular Events(TRACE)
Status:
Completed
Trial end date:
2020-07-10
Target enrollment:
Participant gender:
Summary
To explore the safe and efficacious dose of rhTNK-tPA injection administered within 3 hours
after onset of hyperacute ischemic stroke; to provide dose evidence for phase III clinical
trial.
Phase:
Phase 2
Details
Lead Sponsor:
Beijing Tiantan Hospital
Collaborators:
Baotou Central Hospital First Affiliated Hospital of Jinan University First Hospital of Jilin University Fudan University Guangzhou Recomgen Biotech Co., Ltd. Hebei Medical University Third Hospital Huashan Hospital Inner Mongolia Baogang Hospital Linyi People's Hospital The First Affiliated Hospital of Zhengzhou University The First Hospital of Jilin University The First Hospital Of Qiqihar West China Hospital Yantai Yuhuangding Hospital